Stephenson Harwood, De Marcellus and Disser, Mercure Avocats, Troutman Pepper advised GE Healthcare on the transaction while Goodwin Procter LLP advised the shareholders of Zionexa.
Zionexa, an innovative French start-up focusing on in-vivo biomarkers for targeted therapies in oncology,announced its acquisition by GE Healthcare.
Founded in 2018, Zionexa develops and commercializes molecular imaging solutions for targeted therapies in oncology to improve therapeutic management in the patient’s pathway and provide them a better quality of life.
GE Healthcare is the global leader in contrast products, used in over 100 million imaging procedures worldwide each year.
Stephenson Harwood’s multidisciplinary team was led by Guillaume Briant (Picture) and Boubacar Diao. They were assisted on tax aspects by Olivier Couraud, Dylan Maupas and Youjin Jung and on social law aspects by Soazig Préteseille,Juliette Pagny and Cassandra Coelho.
The Goodwin team was led Thomas Maitrejean and included Simon Servan-Schreiber, Sarah Paquay, Yong Fei Zhu on corporate aspects and Charles-Henri de Gouvion Saint Cyr on tax aspects.
Involved fees earner: Emmanuel de Marcellus – De Marcellus & Disser; Juliette Disser – De Marcellus & Disser; Charles-Henri de Gouvion Saint Cyr – Goodwin Procter; Thomas Maitrejean – Goodwin Procter; Sarah Paquay – Goodwin Procter; Simon Servan-Schreiber – Goodwin Procter; François-Maxime Philizot – Mercure Avocats; Agathe Simon – Mercure Avocats; Guillaume Briant – Stephenson Harwood; Cassandra Coelho – Stephenson Harwood; Olivier Couraud – Stephenson Harwood; Boubacar Diao – Stephenson Harwood; Juliette Pagny – Stephenson Harwood; Youjin Jung – Stephenson Harwood; Dylan Maupas – Stephenson Harwood; Soazig Préteseille – Stephenson Harwood; Timothy Atkins – Troutman Pepper Hamilton Sanders LLP; Andrew Heffler – Troutman Pepper Hamilton Sanders LLP;
Read the full article on Global Legal Chronicle France